Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, January 19, 2020 · 507,582,855 Articles · 3+ Million Readers

Secondary Progressive Multiple Sclerosis (SPMS) Therapeutic and Drug Pipeline Review H2

Wise.Guy12

Wise.Guy.

Secondary Progressive Multiple Sclerosis (SPMS) Treatment Pipeline Review H2 2016

PUNE, INDIA, January 23, 2017 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)
- The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Secondary Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major and minor projects
- The report assesses Secondary Progressive Multiple Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Secondary Progressive Multiple Sclerosis (SPMS) Overview 9
Therapeutics Development 10
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) - Overview 10
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics under Development by Companies 11
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Secondary Progressive Multiple Sclerosis (SPMS) - Products under Development by Companies 16
Secondary Progressive Multiple Sclerosis (SPMS) - Companies Involved in Therapeutics Development 17
AB Science SA 17
Actelion Ltd 18
Biogen, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Genzyme Corporation 21
Glialogix, Inc. 22
Immune Response BioPharma, Inc. 23
Innate Immunotherapeutics Ltd 24
Kyorin Pharmaceutical Co., Ltd. 25
Mallinckrodt Plc 26
MedDay SA 27
MedImmune, LLC 28
Merck KGaA 29
Meta-IQ ApS 30
Novartis AG 31
Opexa Therapeutics, Inc. 32
Xenetic Biosciences (UK) Limited 33
Secondary Progressive Multiple Sclerosis (SPMS) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
7Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
biotin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DC-TAB - Drug Profile 49
Product Description 49

Access Report @ https://www.wiseguyreports.com/reports/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release